abstract |
A method of improving muscle or limb performance in a subject suffering from or at risk of a disorder associated with muscle atrophy, muscle adipose tissue, or pseudohypertrophy or muscular dystrophy by administering sufficient to improve muscle A pharmaceutical composition targeting CD49d of one or more markers, signs or parameters of fat, muscle performance or function, or limb performance or function. Inhibitory oligonucleotides. A method comprising the steps of: (i) determining the level of CD4+CD49d+ T cells in a blood sample from a subject; (ii) administering a course of antisense oligonucleotides and near the end of the dosing cycle Repeat step (i) at least once; (iii) repeat step (i) within one week of completion of dosing; (iv) process results to determine whether the subject exhibits or does not exhibit at the level of CD4+CD49d+ T cells Rebound, stability, or loss after dose completion. |